Clinical implications of ANCA positivity in a hospital setting: a tertiary center experience.


Journal

Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 22 07 2020
accepted: 25 09 2020
pubmed: 8 10 2020
medline: 14 9 2021
entrez: 7 10 2020
Statut: ppublish

Résumé

ANCA testing plays an established critical role in the diagnosis of ANCA Associated vasculitis (AAV). The spectrum of diseases associated with positive ANCA has recently broadened, thus calling into question the diagnostic implications of ANCA positivity in a hospital setting. We retrospectively studied all adult patients who had a positive ANCA test (by Indirect Immunofluorescence (IIF), ELISA or both) performed over the span of 19 years. Subjects were then divided into discordant (positive on one assay) and concordant ANCA (positive on both assays) groups based on their ANCA positivity status. The two groups were then compared with regards to their demographic, clinical and laboratory characteristics, the indication for ANCA testing in both groups and their final diagnoses. Of the 9189 ANCA tests ordered during the 19-year span of the study, 389 (4.2%) were positive. Two hundred and forty subjects met the exclusion criteria (patients aged less than 18 years or the lack of clinical and laboratory data in the medical file) thus resulting in a final cohort of 149 subjects. Of them, 122 subjects had discrepant ANCA results and 27 had matching ANCA results. Most cases in the discrepancy group were IIF positive and ELISA negative (86.8%). The diagnosis of AAV was highly unlikely in cases with discrepant IIF and ELISA serologies compared to cases with matching IIF and ELISA serologies (4.1% versus 44.4%, p value < 0.001). The diagnosis of AAV in unlikely in subjects with discrepancies between IIF and ELISA, particularly with only positive IIF.

Identifiants

pubmed: 33025533
doi: 10.1007/s11739-020-02518-6
pii: 10.1007/s11739-020-02518-6
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

429-436

Commentaires et corrections

Type : CommentIn

Références

Savige J, Gillis DF, Benson E, Davies DF, Esnault VF, Falk R, Hagen EC, Jayne D, Jennette J, Paspaliaris B, Pollock W, Pusey C, Savage C, Silvestrini R, Woude F, Wieslander J, Wiik A (1999) International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 111:507–513. https://doi.org/10.1093/ajcp/111.4.507
doi: 10.1093/ajcp/111.4.507 pubmed: 10191771
Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suarez LF, Guillevin L, Hellmich B, Jayne D, Jennette JC, Kallenberg CGM, Moiseev S, Novikov P, Radice A, Savige JA, Sinico RA, Specks U, van Paassen P, Zhao MH, Rasmussen N, Damoiseaux J, Csernok E (2017) Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13(11):683–692. https://doi.org/10.1038/nrrheum.2017.140
doi: 10.1038/nrrheum.2017.140 pubmed: 28905856
Abdulkader R, Lane SE, Scott DGI, Watts RA (2013) Classification of vasculitis: EMA classification using CHCC 2012 definitions. Ann Rheum Dis 72(11):1888–1888. https://doi.org/10.1136/annrheumdis-2013-203511
doi: 10.1136/annrheumdis-2013-203511 pubmed: 23727632
Arnold DF, Timms A, Luqmani R, Misbah SA (2010) Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? an audit of 263 patients. J Clin Pathol 63(8):678–680. https://doi.org/10.1136/jcp.2009.072504
doi: 10.1136/jcp.2009.072504 pubmed: 20702467
Mandl L, Solomon D, Smith E, Lew R, Katz J, Shmerling R (2002) Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis. Arch Intern Med 162:1509–1514. https://doi.org/10.1001/archinte.162.13.1509
doi: 10.1001/archinte.162.13.1509 pubmed: 12090888
Radice A, Sinico RA (2005) Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 38(1):93–103. https://doi.org/10.1080/08916930400022673
doi: 10.1080/08916930400022673 pubmed: 15804710
Hoffman GS, Specks U (1998) Antineutrophil cytoplasmic antibodies. Arthritis Rheum 41(9):1521–1537. https://doi.org/10.1002/1529-0131(199809)41:9<1521:AID-ART2>3.0.CO;2-A
doi: 10.1002/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A pubmed: 9751084
Nässberger L, Jonsson H, Sjoholm AG, Sturfelt G, Heubner A (1989) Circulating anti-elastase in systemic lupus erythematosus. The Lancet 333(8636):509. https://doi.org/10.1016/S0140-6736(89)91420-7
doi: 10.1016/S0140-6736(89)91420-7
Kuwana T, Sato Y, Saka M, Kondo Y, Miyata M, Obara K, Nishimaki T, Kasukawa R (2000) Anti-cathepsin G antibodies in the sera of patients with ulcerative colitis. J Gastroenterol 35:682–689. https://doi.org/10.1007/s005350070047
doi: 10.1007/s005350070047 pubmed: 11023039
Talor MV, Stone JH, Stebbing J, Barin J, Rose NR, Burek CL (2007) Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 150(1):42–48. https://doi.org/10.1111/j.1365-2249.2007.03453.x
doi: 10.1111/j.1365-2249.2007.03453.x pubmed: 17614969 pmcid: 2219289
Peter HH, Metzger D, Rump A, Röther E (1993) ANCA in diseases other than systemic vasculitis. Clin Exp Immunol 93(Suppl 1):12–14. https://doi.org/10.1111/j.1365-2249.1993.tb06217.x
doi: 10.1111/j.1365-2249.1993.tb06217.x pubmed: 8365018 pmcid: 1554934
Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, Marcolongo R, Cervera R, De Ramòn GE, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Mathieu A, Papasteriades C, Piette JC, Scorza R, Smolen J (1998) Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the immunogenetics of SLE. Clin Exp Rheumatol 16(5):541–546
pubmed: 9779300
Subra JF, Michelet C, Laporte J, Carrere F, Reboul P, Cartier F, Saint-André JP, Chevailler A (1998) The presence of cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) in the course of subacute bacterial endocarditis with glomerular involvement, coincidence or association? Clin Nephrol 49(1):15–18
pubmed: 9491280
Savige JA, Gallicchio MC, Stockman A, Cunningham TJ, Rowley MJ, Georgiou T, Davies D (1991) Anti-neutrophil cytoplasm antibodies in rheumatoid arthritis. Clin Exp Immunol 86(1):92–98. https://doi.org/10.1111/j.1365-2249.1991.tb05779.x
doi: 10.1111/j.1365-2249.1991.tb05779.x pubmed: 1655318 pmcid: 1554154
Moiseev S, Cohen Tervaert JW, Arimura Y, Bogdanos DP, Csernok E, Damoiseaux J, Ferrante M, Flores-Suarez LF, Fritzler MJ, Invernizzi P, Jayne D, Jennette JC, Little MA, McAdoo SP, Novikov P, Pusey CD, Radice A, Salama AD, Savige JA, Segelmark M, Shoenfeld Y, Sinico RA, Sousa MJ, Specks U, Terrier B, Tzioufas AG, Vermeire S, Zhao MH, Bossuyt X (2020) 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev 19(9):102618. https://doi.org/10.1016/j.autrev.2020.102618
doi: 10.1016/j.autrev.2020.102618 pubmed: 32663621
Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Ludemann J, Rasmussen N, Sinico RA, Wiik A, van der Woude FJ (1998) Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR project for ANCA assay standardization. Kidney Int 53(3):743–753. https://doi.org/10.1046/j.1523-1755.1998.00807.x
doi: 10.1046/j.1523-1755.1998.00807.x pubmed: 9507222
Choi HK, Liu S, Merkel PA, Colditz GA, Niles JL (2001) Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol 28(7):1584–1590
pubmed: 11469466
Kawamura T, Usui J, Kaneko S, Tsunoda R, Imai E, Kai H, Morito N, Saito C, Nagata M, Yamagata K (2017) Anaemia is an essential complication of ANCA-associated renal vasculitis: a single center cohort study. BMC Nephrol 18(1):337. https://doi.org/10.1186/s12882-017-0754-8
doi: 10.1186/s12882-017-0754-8 pubmed: 29178888 pmcid: 5702204
Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3):488–494. https://doi.org/10.1136/ard.2010.137778
doi: 10.1136/ard.2010.137778 pubmed: 21109517
Moon JS, Lee DD, Park YB, Lee SW (2018) Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor. Clin Rheumatol 37(10):2771–2779. https://doi.org/10.1007/s10067-017-3902-4
doi: 10.1007/s10067-017-3902-4 pubmed: 29119480

Auteurs

Bashar Fteiha (B)

Department of Medicine, Shaare Zedek Medical Center, 12 Shmuel Bait St, PO Box 3235, 91031022, Jerusalem, Israel. basharf@szmc.org.il.

Alon Bnaya (A)

Department of Medicine, Shaare Zedek Medical Center, 12 Shmuel Bait St, PO Box 3235, 91031022, Jerusalem, Israel.
Nephrology Unit, Shaare Zedek Medical Center, 12 Shmuel Bait St., PO Box 3235, 9103102, Jerusalem, Israel.

Marwan Abu Sneineh (M)

Department of Medicine, Shaare Zedek Medical Center, 12 Shmuel Bait St, PO Box 3235, 91031022, Jerusalem, Israel.

Gideon Nesher (G)

Department of Medicine, Shaare Zedek Medical Center, 12 Shmuel Bait St, PO Box 3235, 91031022, Jerusalem, Israel.
Rheumatology Unit, Shaare Zedek Medical Center, 12 Shmuel Bait St., PO Box 3235, 9103102, Jerusalem, Israel.
Hadassah Hebrew University School of Medicine, 9112001, Jerusalem, Israel.

Gabriel Simon Breuer (GS)

Department of Medicine, Shaare Zedek Medical Center, 12 Shmuel Bait St, PO Box 3235, 91031022, Jerusalem, Israel.
Rheumatology Unit, Shaare Zedek Medical Center, 12 Shmuel Bait St., PO Box 3235, 9103102, Jerusalem, Israel.
Hadassah Hebrew University School of Medicine, 9112001, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH